<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Survival outcomes in sentinel node-positive vs. -negative endometrial cancer following adjustment for uterine risk factors: a propensity score-matched analysis (TRSGO-SLN-011)

dc.contributor.authorYalcin, Ibrahim
dc.contributor.authorArslan, Oguz
dc.contributor.authorGokce, Ali
dc.contributor.authorSozen, Hamdullah
dc.contributor.authorKumtepe, Yakup
dc.contributor.authorOzturk, Cagatayhan
dc.contributor.authorToyran, Atahan
dc.contributor.authorTakmaz, Ozguc
dc.contributor.authorTopuz, Samet
dc.contributor.authorVatansever, Dogan
dc.contributor.authorTaskiran, Cagatay
dc.contributor.authorDogan, Nasuh Utku
dc.contributor.authorGungor, Mete
dc.contributor.authorOrtac, Firat
dc.contributor.authorTaskin, Salih
dc.date.accessioned2026-11-05T11:07:40Z
dc.date.issued2026
dc.description.abstractObjective: To evaluate the association between sentinel lymph node status and survival outcomes in cases of endometrial cancer and to identify prognostic factors. Methods: Our multicenter retrospective study included 1473 cases of clinically early-stage endometrial cancer evaluated by sentinel lymph node mapping between 2014 and 2023. After excluding 89 cases due to missing data, 1384 cases were analyzed, including 1282 patients found to have negative sentinel lymph nodes and 102 with positive sentinel lymph nodes. Propensity score matching (1:1) was performed using histological subtypes, tumor grades, myometrial invasion depths, and lymphovascular space and cervical stromal invasion statuses. Of the 102 patients found to have sentinel lymph node positivity, 73 were successfully matched to 73 patients from the negative group. Results: After a median follow-up duration of 52 months, no statistical difference was noted between patients with positive and negative sentinel lymph nodes for 5-year disease-free survival (60.3% and 78.6%, respectively; p = 0.162) or 5-year overall survival (71.1% and 86.7%; p = 0.255). Multivariable analysis indicated that tumor grade 3 could independently predict decreased disease-free survival (HR: 3.04; 95% CI: 1.37-6.74; p = 0.006). However, no independent prognostic factors were determined for overall survival. Conclusion: After adjustment for uterine risk factors, sentinel lymph node status was no statistically significant independent association detected with survival outcomes. Prognosis was found to be shaped by an integrated set of uterine risk factors that included sentinel lymph node status, highlighting the need to individualize adjuvant treatment according to the complete tumor risk profile.
dc.description.pages115053
dc.description.volume321
dc.identifier.doi10.1016/j.ejogrb.2026.115053
dc.identifier.issn0301-2115
dc.identifier.issn1872-7654
dc.identifier.urihttps://doi.org/10.1016/j.ejogrb.2026.115053
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/11472
dc.identifier.wosWOS:001712574700001
dc.language.isoen
dc.publisherELSEVIER
dc.relation.hasversion10.1016/j.ejogrb.2026.115053
dc.relation.ispartofEUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY
dc.subjectAdjuvant therapy
dc.subjectEndometrial neoplasms
dc.subjectSentinel lymph node
dc.subjectSurvival
dc.subjectObstetrics & Gynecology
dc.subjectReproductive Biology
dc.titleSurvival outcomes in sentinel node-positive vs. -negative endometrial cancer following adjustment for uterine risk factors: a propensity score-matched analysis (TRSGO-SLN-011)
dc.typeArticle
oaire.citation.editionScience Citation Index Expanded (SCI-EXPANDED)
oaire.citation.volume321
person.identifier.ridAAI-4940-2020
person.identifier.ridC-5630-2016
person.identifier.ridADY-4887-2022
person.identifier.ridAAY-8615-2020
person.identifier.ridMXK-4547-2025
person.identifier.ridHDO-3899-2022
person.identifier.ridA-9611-2015
person.identifier.ridKFR-7410-2024
person.identifier.ridABB-6538-2020
person.identifier.ridAAI-5118-2020
person.identifier.ridJPX-8468-2023
person.identifier.ridX-4933-2018

Files

Collections